News

New research builds on evidence that diet, certain brain training exercises and physical activity can delay the decline of ...
Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.
Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...
ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of ...
All forms of walking can provide mental health benefits. When you walk, your body releases mood-boosting hormones including ...
A new study analyzing 57 research papers finds that 7,000 daily steps provides substantial health benefits, challenging the ...
Japanese drugmaker JCR Pharmaceuticals has entered into a joint collaboration, option and license agreement with US biotech Acumen Pharmaceuticals to develop a novel therapeutic candidate for the ...
Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...
A stroke drug called GAI-17 protected mouse brains even six hours after damage began—and may one day help fight Alzheimer’s ...